Literature DB >> 28141543

Molecular challenges imposed by MHC-I restricted long epitopes on T cell immunity.

Tracy M Josephs1, Emma J Grant1, Stephanie Gras1.   

Abstract

It has widely been accepted that major histocompatibility complex class I molecules (MHC-I) are limited to binding small peptides of 8-10 residues in length. However, this consensus has recently been challenged with the identification of longer peptides (≥11 residues) that can also elicit cytotoxic CD8+ T cell responses. Indeed, a growing number of studies demonstrate that these non-canonical epitopes are important targets for the immune system. As long epitopes represent up to 10% of the peptide repertoire bound to MHC-I molecules, here we review their impact on antigen presentation by MHC-I, TCR recognition, and T cell immunity.

Keywords:  T cell receptor recognition; antigen presentation; human leukocyte antigen; major histocompatibility complex; tumor peptide; viral peptide

Mesh:

Substances:

Year:  2017        PMID: 28141543     DOI: 10.1515/hsz-2016-0305

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  13 in total

1.  Computational Alanine Scanning Reveals Common Features of TCR/pMHC Recognition in HLA-DQ8-Associated Celiac Disease.

Authors:  Linqiong Qiu; Jianing Song; John Z H Zhang
Journal:  Methods Mol Biol       Date:  2022

2.  Overlapping Peptides Elicit Distinct CD8+ T Cell Responses following Influenza A Virus Infection.

Authors:  Lisa M Assmus; Jing Guan; Ting Wu; Carine Farenc; Xavier Y X Sng; Pirooz Zareie; Angela Nguyen; Andrea T Nguyen; David C Tscharke; Paul G Thomas; Jamie Rossjohn; Stephanie Gras; Nathan P Croft; Anthony W Purcell; Nicole L La Gruta
Journal:  J Immunol       Date:  2020-08-31       Impact factor: 5.422

3.  PTAP motif duplication in the p6 Gag protein confers a replication advantage on HIV-1 subtype C.

Authors:  Shilpee Sharma; Prabhu S Arunachalam; Malini Menon; Viswanath Ragupathy; Ravi Vijaya Satya; Joshua Jebaraj; Shambhu Ganeshappa Aralaguppe; Chaitra Rao; Sreshtha Pal; Shanmugam Saravanan; Kailapuri G Murugavel; Pachamuthu Balakrishnan; Suniti Solomon; Indira Hewlett; Udaykumar Ranga
Journal:  J Biol Chem       Date:  2018-05-17       Impact factor: 5.157

Review 4.  The intersection of affinity and specificity in the development and optimization of T cell receptor based therapeutics.

Authors:  Timothy P Riley; Brian M Baker
Journal:  Semin Cell Dev Biol       Date:  2018-12       Impact factor: 7.499

5.  Dual non-contiguous peptide occupancy of HLA class I evoke antiviral human CD8 T cell response and form neo-epitopes with self-antigens.

Authors:  Ziwei Xiao; Zhiyong Ye; Vikeramjeet Singh Tadwal; Meixin Shen; Ee Chee Ren
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

6.  Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide.

Authors:  Kok Fei Chan; Benjamin S Gully; Stephanie Gras; Dennis X Beringer; Lars Kjer-Nielsen; Jonathan Cebon; James McCluskey; Weisan Chen; Jamie Rossjohn
Journal:  Nat Commun       Date:  2018-03-12       Impact factor: 14.919

Review 7.  The role of neoantigen in immune checkpoint blockade therapy.

Authors:  Ming Yi; Shuang Qin; Weiheng Zhao; Shengnan Yu; Qian Chu; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2018-11-16

8.  Unusual Placement of an EBV Epitope into the Groove of the Ankylosing Spondylitis-Associated HLA-B27 Allele Allows CD8+ T Cell Activation.

Authors:  Valentina Tedeschi; Josephine Alba; Fabiana Paladini; Marino Paroli; Alberto Cauli; Alessandro Mathieu; Rosa Sorrentino; Marco D'Abramo; Maria Teresa Fiorillo
Journal:  Cells       Date:  2019-06-11       Impact factor: 6.600

9.  Crystal structure of suboptimal viral fragments of Epstein Barr Virus Rta peptide-HLA complex that stimulate CD8 T cell response.

Authors:  Xuelu Huan; Ziyi Zhuo; Ziwei Xiao; Ee Chee Ren
Journal:  Sci Rep       Date:  2019-11-13       Impact factor: 4.379

10.  Challenging immunodominance of influenza-specific CD8+ T cell responses restricted by the risk-associated HLA-A*68:01 allomorph.

Authors:  C E van de Sandt; E B Clemens; E J Grant; L C Rowntree; S Sant; H Halim; J Crowe; A C Cheng; T C Kotsimbos; M Richards; A Miller; S Y C Tong; J Rossjohn; T H O Nguyen; S Gras; W Chen; K Kedzierska
Journal:  Nat Commun       Date:  2019-12-06       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.